(140) SGLT2 inhibitors and Parkinson’s disease (PD) risk in older populations with type 2 diabetes (T2D)

Background: Parkson's disease (PD) affects millions of individuals worldwide, however, there is no cure for the condition.

Objectives: We aimed to assess the association between SGLT2 inhibitors and PD risk for drug re-purposing.

Methods: In this retrospective cohort study, we used 2016-2020 national Medicare Claims data to identify beneficiaries with type 2 diabetes (T2D) and without preexisting PD. We compared the risk of PD between new users of SGLT2 inhibitors vs. DPP4 inhibitors. We employed 1:1 propensity score matching to balance the baseline confoundings between the treatment groups and applied Cox regression models to estimate the PD risk.

Results: After 1:1 propensity score matching, 26,619 individuals were included in each of the two treatment groups, the PD incidence was 2.48 and 3.54 per 1000 person-years in the SGLT2 inhibitor group and DPP4 inhibitor group, respectively. In the Cox model (Figure), the SGLT2 inhibitor group was associated with a significantly lower risk of incident PD (HR 0.70 [95% CI 0.55-0.89]) than the DPP4 inhibitor group. The risk reduction of PD was particularly profound in non-Hispanic Black individuals (HR 0.24 [95% CI 0.07-0.86]) and insulin users (HR 0.49 [95% CI 0.32-0.77]).

Conclusions: Compared to DPP4 inhibitors, SGLT2 inhibitors were associated with a significantly lower risk of indecent PD in people with T2D.